Benjamin P Linas
Affiliation: Massachusetts General Hospital
- Assessing the impact of federal HIV prevention spending on HIV testing and awarenessBenjamin P Linas
Massachusetts General Hospital, 50 Staniford St, Ninth Floor, Boston, MA 02114, USA
Am J Public Health 96:1038-43. 2006..The United States allocates more than $900 million annually for the prevention of HIV infection. We assessed the impact of this funding on HIV testing and knowledge...
- Optimizing resource allocation in United States AIDS drug assistance programsBenjamin P Linas
Division of General Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
Clin Infect Dis 43:1357-64. 2006..We hypothesized that CD4 cell count-based ADAP eligibility would improve ADAP outcomes, allowing them to serve more-diverse patient populations and to prioritize persons who are at greatest risk of HIV-related mortality...
- Improving outcomes in state AIDS drug assistance programsBenjamin P Linas
Divisions of General Medicine, Massachusetts General Hospital, Boston, MA 02115, USA
J Acquir Immune Defic Syndr 51:513-21. 2009..State AIDS Drug Assistance Programs (ADAPs) provide antiretroviral medications to patients with no access to medications. Resource constraints limit the ability of many ADAPs to meet demand for services...
- The impact of HIV/HCV co-infection on health care utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) CohortB P Linas
Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA 02114, USA
J Viral Hepat 18:506-12. 2011..5), 1.7 (95% CI: 1.4-2.1), and 1.6 (95% CI: 1.3-1.9) respectively. Programs serving HIV/HCV co-infected patients can expect approximately 70% higher rates of utilization than expected from a similar cohort of HIV mono-infected patients...
- Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DCRochelle P Walensky
Division of Infectious Disease, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
Clin Infect Dis 51:392-400. 2010..We forecast outcomes of this approach if implemented in Washington DC...
- When to start antiretroviral therapy in resource-limited settingsRochelle P Walensky
Massachusetts General Hospital, Brigham and Women s Hospital, Harvard University Medical School, Harvard School of Public Health, and Boston University School of Public Health, Boston, Massachusetts 02114, USA
Ann Intern Med 151:157-66. 2009..The results of international clinical trials that are assessing when to initiate antiretroviral therapy (ART) will not be available for several years...
- Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with menBenjamin P Linas
HIV Epidemiology and Outcomes Research Unit, Section of Infectious Diseases, Boston Medical Center, Boston, MA 02118, USA
Clin Infect Dis 55:279-90. 2012..We used a Monte Carlo computer simulation to estimate the effectiveness and cost-effectiveness of screening for acute hepatitis C virus (HCV) infection in human immunodeficiency virus (HIV)-infected men who have sex with men...
- WHO 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe: modeling clinical outcomes in infants and mothersAndrea L Ciaranello
Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, United States of America
PLoS ONE 6:e20224. 2011..The Zimbabwean national prevention of mother-to-child HIV transmission (PMTCT) program provided primarily single-dose nevirapine (sdNVP) from 2002-2009 and is currently replacing sdNVP with more effective antiretroviral (ARV) regimens...
- First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trialAndrea L Ciaranello
Division of Infectious Disease, Massachusetts General Hospital, Boston, 02114, USA
AIDS 25:479-92. 2011..nevirapine-based antiretroviral therapy (ART) among women previously exposed to single-dose nevirapine to prevent mother-to-child HIV transmission. However, lopinavir/ritonavir is 12 times costlier than nevirapine...
- Improving HIV and HCV outcomes in U.S. AIDS Drug Assistance ProgramsBENJAMIN LINAS; Fiscal Year: 2007..This K01 award will lead to a novel, independent trajectory of research, and will inform HIV and HCV care and policy in the United States. ..